Notice of Intent to Publish a Funding Opportunity Announcement for the Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN)
ID: 338903Type: Forecasted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/338903
Timeline
    Description

    The National Institutes of Health (NIH) plans to publish a Funding Opportunity Announcement (FOA) for the Rare Diseases Clinical Research Consortia (RDCRC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to enhance the diagnosis, management, and treatment of rare diseases through collaborative, multi-site, patient-centric research, with a strong emphasis on addressing unmet clinical trial readiness needs. The estimated total program funding is $1,000,000, and the FOA is expected to be published in 2024, with applications due later that year. For further inquiries, interested applicants can contact Dr. Tiina K. Urv at 301-827-2746 or via email at urvtiin@mail.nih.gov.

    Point(s) of Contact
    Tiina K. Urv, Ph.D.
    (301) 827-2746
    urvtiin@mail.nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Notice of Intent to Publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to solicit applications for collaborative, multi-site research focused on advancing the diagnosis, management, and treatment of rare diseases, with an emphasis on addressing unmet clinical trial readiness needs. The funding, estimated at $1 million, will support specialized centers through cooperative agreements, with the NOFO expected to be published in winter 2024 and applications due in summer 2024. Interested applicants should prepare to develop meaningful collaborations, as the estimated award date is set for July 1, 2025.
    Notice of Intent to Publish a Funding Opportunity Announcement for Data Management and Coordinating Center (DMCC) for Rare Diseases Clinical Research Network (RDCRN) (U2C Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Funding Opportunity Announcement (FOA) for the establishment of a Data Management and Coordinating Center (DMCC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to enhance the diagnosis, management, and treatment of rare diseases by facilitating collaborative, multi-site, patient-centric research through the RDCRN and supporting the activities of the Rare Diseases Clinical Research Consortia (RDCRC). The estimated total program funding for this grant is $1,000,000, with the FOA expected to be published in 2024 and awards anticipated in 2025. Interested applicants can reach out to Dr. Tiina K. Urv at urvtiin@mail.nih.gov or by phone at 301-827-2746 for further information.
    Notice of Intent to Publish the re-issuance of the Notice of Funding Opportunity (NOFO) Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN) (U54 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to re-issue the Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) under the Rare Diseases Clinical Research Network (RDCRN), aimed at enhancing research in the diagnosis, management, and treatment of rare diseases. Each RDCRC is required to focus on at least three rare diseases and propose two to four clinical research projects, including one longitudinal study, emphasizing a collaborative, multi-site approach to address significant clinical trial readiness gaps. This initiative reflects the government's commitment to advancing public health through innovative methodologies and stakeholder engagement in the rare disease domain, with applications expected to be due in June and fall of 2025. Interested applicants can reach out to Dr. Tiina K. Urv at 301-827-2746 or via email at urvtiin@mail.nih.gov for further information.
    Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition for the Continuation of Clinical Sites for the Undiagnosed Diseases Network (U01 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Funding Opportunity Announcement (FOA) for a Limited Competition aimed at continuing the support for Clinical Sites within the Undiagnosed Diseases Network (UDN). This initiative is specifically designed for institutions and Program Directors/Principal Investigators who have previously received NIH funding under the UDN program, allowing them to compete for an additional year of funding to enhance their participation, establish collaborations, and develop sustainability plans as the network transitions into a national resource. The total estimated program funding is $6.5 million, with an award ceiling of $400,000 and an expected 11 awards to be made. Interested applicants should note that the FOA is anticipated to be published in August 2022, with applications due by September 2022. For further inquiries, potential applicants can contact Dr. Argenia Doss at argenia.doss@nih.gov or by phone at 301-827-1373.
    Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)" aimed at supporting clinical projects that enhance readiness for clinical trials in rare diseases. This initiative seeks applications that focus on developing and testing biomarkers and clinical outcome measures, as well as defining the characteristics of rare diseases to facilitate the design of future clinical trials. The program is particularly important for addressing the needs of rare diseases affecting fewer than 200,000 individuals in the U.S., with a maximum budget of $275,000 for direct costs over a project period of up to two years. Interested applicants can find more information and submit inquiries via email to grantsinfo@nih.gov, with the application deadline set for July 20, 2028.
    Forecast for Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the R21 grant aimed at enhancing clinical trial readiness for rare diseases, disorders, and syndromes. This initiative seeks to support research projects that address critical needs in the field, such as the development of biomarkers and clinical outcome measures, which are essential for facilitating the transition of therapeutics and diagnostics into clinical trials. The opportunity is particularly significant as it aims to improve the success rates of clinical trials for rare diseases, which often face unique challenges. Interested small businesses are encouraged to begin forming collaborations and developing proposals, with the estimated synopsis posting date set for November 14, 2025, and applications expected to be accepted until February 16, 2026. For further inquiries, potential applicants can contact Dr. Alice Chen Grady at alice.chen2@nih.gov or by phone at 301-827-2015.
    Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)" aimed at supporting preclinical efficacy studies for therapeutic agents targeting rare diseases. This initiative seeks to fund projects that demonstrate the effectiveness of proposed treatments in established rare disease models, along with necessary pharmacodynamic and pharmacokinetic studies, to facilitate further development towards Investigational New Drug (IND) applications or clinical trials. With a total funding budget of up to $1.2 million, the NIH anticipates awarding 3-5 grants, each with a maximum budget of $275,000 over a two-year project period. Interested applicants must submit letters of intent by May 1, 2024, with full applications due by May 3, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Notice of Intent to Publish a Funding Opportunity Announcement for Diagnostic Centers of Excellence (X01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity announcement for the establishment of Diagnostic Centers of Excellence (DCoE) as part of the Undiagnosed Diseases Network (UDN). The initiative aims to enhance the diagnostic journey for patients with undiagnosed diseases by creating a self-sustained network that provides expert diagnostic services and fosters scientific discovery, with a focus on utilizing genomics data. Eligible applicants will be clinical sites in the U.S. that can demonstrate the necessary infrastructure and expertise to conduct clinical evaluations and DNA sequencing, with the opportunity to enroll a minimum of five participants annually. Interested parties can contact Dr. Argenia Doss at argenia.doss@nih.gov or by phone at 301-827-1373 for further details. The program announcement is expected to be published in spring 2023, with applications due in early summer 2023, and the maximum period of performance for awarded projects will be five years.
    GREGoRi Data Coordination and Outreach Center (U01, Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the establishment of the GREGoRi Data Coordination and Outreach Center, aimed at advancing the Genomics Research to Elucidate the Genetics of Rare Disease (GREGoR) program. This initiative seeks to enhance the diagnosis of rare genetic disorders by developing innovative tools and analytical methods to identify causal genes and variants, with the center serving as the primary coordination hub for data and resources generated by the GREGoRi program. The total estimated funding for this cooperative agreement is $2 million, with one award anticipated, and applications are expected to be due in 2026 following the publication of the Notice of Funding Opportunity (NOFO) in 2025. For further inquiries, interested applicants can contact Lisa H. Chadwick at lisa.chadwick@nih.gov or by phone at 301-435-7275.
    Reissue of RFA-FD-23-001- Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01 Clinical Trials Required)
    Food and Drug Administration
    The U.S. Food and Drug Administration (FDA) has announced a Notice of Funding Opportunity (NOFO) titled "Reissue of RFA-FD-23-001 - Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01 Clinical Trials Required)." This initiative aims to fund clinical trials that evaluate the efficacy and safety of orphan products for rare diseases, with the goal of addressing unmet medical needs and increasing the number of approved treatments in this area. The funding opportunity encourages innovative trial designs and collaboration among various stakeholders, emphasizing the importance of patient engagement throughout the research process. Eligible applicants include a wide range of organizations, with funding amounts reaching up to $900,000 per year, and applications are due by May 16, 2028. For further inquiries, interested parties can contact Kimberly Pendleton at Kimberly.Pendleton@fda.hhs.gov.